Parkinson & movement disorder (pmd) alliance and neurocrine biosciences announce new survey results revealing the significant impact off time has on people with parkinson's disease and their care partners

86 percent of people with parkinson's disease (pd) (n=113) taking the survey experience off time daily, and a majority report it has a significant impact on activities while three in four people with pd (78%) report that their current treatment plan is effective at limiting their pd symptoms, over half (56%) also say that they don't think their symptoms can improve beyond their current state san diego , sept. 12, 2022 /prnewswire/ -- parkinson & movement disorder (pmd) alliance, in partnership with neurocrine biosciences (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating disorders, today announced results from the survey assessment: impact of off time on people with parkinson's disease and their care partners.
NBIX Ratings Summary
NBIX Quant Ranking